Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Indivior Pharmaceuticals Inc INDV

Healthcare Drug Manufacturers - Specialty & Generic
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release... see more

Current News (NDAQ:INDV)

Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ

GlobeNewswire January 28, 2026

Indivior Announces Completion of Redomiciliation to the United States

GlobeNewswire January 26, 2026

Indivior Provides Full-Year 2026 Financial Guidance and Business Update

GlobeNewswire January 8, 2026

Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference

PR Newswire November 19, 2025

Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine

PR Newswire November 3, 2025

Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment

PR Newswire October 15, 2025

Indivior to Participate in Upcoming Investor Events

PR Newswire August 20, 2025

Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance

PR Newswire July 31, 2025

FINAL INDV DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Indivior PLC Investors to Join the Class Action Lawsuit

Newsfile October 1, 2024
View More News ››

Opinion & Analysis (NDAQ:INDV)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:INDV)

Be the first to post on this bullboard.

TomaGold Corp.

TomaGold Corp.

TomaGold Corporation, together with its subsidiaries, engages in the acquisition, exploration, assessment, and development of ...
View More »

Podcasts